Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Patients with myelodysplastic syndrome (MDS) who are treated with azacitidine before allogeneic stem-cell transplantation fare as well as patients receiving standard pre-transplant induction…
One of the most common dietary supplements taken by many American adults is a daily multivitamin. Recently, a new study found that men over 50 who took a…
NEW YORK (Reuters Health) – Even the best strategies for selectively testing colorectal CRC tumors for mismatch repair (MMR) gene mutations will miss 5% to 15% of Lynch…
NEW YORK (Reuters Health) – The use of tumor necrosis factor alpha inhibitors (TNF-I) therapy for various immune-mediated chronic inflammatory diseases does not increase the risk of cancer,…
NEW YORK (Reuters Health) – Two independent studies have shown that long-term outcomes are better with radiotherapy and chemotherapy rather than radiotherapy alone in patients with anaplastic oligodendrogliomas…
NEW YORK (Reuters Health) – Complete bladder neck preservation during radical prostatectomy improves the rate of urinary continence subsequently, a German team reports. Furthermore, the strategy is associated…
NEW YORK (Reuters Health) – A test that measures levels of the protein fibulin-3 in blood and pleural fluid can identify people with pleural mesothelioma and might someday…
NEW YORK (Reuters Health) – Intravesical bacille Calmette-Guérin (BCG) therapy for bladder cancer is associated with eradication of uropathogens in patients not taking antibiotics, according to a new…
NEW YORK (Reuters Health) – Children with cancer who develop fever and neutropenia and who are at high risk for invasive fungal disease should be treated empirically with…
NEW YORK (Reuters Health) – Despite its known cardiotoxic effect, trastuzumab is associated with a relatively low risk of congestive heart failure in women being treated for HER2-positive…
